Skip to main content
. Author manuscript; available in PMC: 2010 Dec 21.
Published in final edited form as: Bioconjug Chem. 2009 Jul 15;20(8):1559–1568. doi: 10.1021/bc9001739

Figure 5.

Figure 5

A: the relationship between tumor size and tumor uptake for 99mTcO(MAG2-3P-RGD2) at 120 min p.i. in the athymic nude mice (n = 14) bearing the U87MG glioma xenografts. The linear relationship between the tumor size and %ID tumor uptake suggests that 99mTcO(MAG2-3P-RGD2) has the potential for noninvasive monitoring of tumor growth or shrinkage during anti-angiogenic therapy. B: planar images of the athymic nude mice (bearing U87MG glioma xenografts) administered with ∼500 μCi of 99mTcO(MAG2-3P-RGD2) at 15, 30, 60 and 120 min p.i. Arrows indicate the presence of the tumor, gallbladder, kidneys and bladder.